| Index | — | P/E | 31.70 | EPS (ttm) | 2.66 | Insider Own | 5.70% | Shs Outstand | 59.71M | Perf Week | -10.50% |
| Market Cap | 5.03B | Forward P/E | 18.06 | EPS next Y | 4.67 | Insider Trans | -0.72% | Shs Float | 58.30M | Perf Month | -1.24% |
| Enterprise Value | 5.34B | PEG | 5.13 | EPS next Q | 1.12 | Short Float | 6.51% | Perf Quarter | -1.76% | ||
| Income | 160.00M | P/S | 3.12 | EPS this Y | 16.04% | Short Ratio | 4.76 | Perf Half Y | 35.96% | ||
| Sales | 1.61B | P/B | 2.88 | EPS next Y | 7.29% | ROA | 5.47% | Short Interest | 3.79M | Perf YTD | -4.35% |
| Book/sh | 29.22 | P/C | 9.99 | EPS next 5Y | 6.18% | ROE | 9.65% | 52W High | 94.85 -11.11% | Perf Year | 1.53% |
| Cash/sh | 8.44 | P/FCF | 24.68 | EPS past 3/5Y | 18.19% — | ROIC | 6.16% | 52W Low | 59.74 41.13% | Perf 3Y | 32.79% |
| Dividend Est. | — | EV/EBITDA | 14.17 | Sales past 3/5Y | 9.59% 9.46% | Gross Margin | 49.41% | Volatility | 3.69% 2.88% | Perf 5Y | 23.60% |
| Dividend TTM | — | EV/Sales | 3.32 | EPS Y/Y TTM | 36.41% | Oper. Margin | 13.49% | ATR (14) | 2.69 | Perf 10Y | 256.49% |
| Dividend Ex-Date | — | Quick Ratio | 3.05 | Sales Y/Y TTM | 9.22% | Profit Margin | 9.94% | RSI (14) | 37.54 | Recom | 2.27 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.52 | EPS Q/Q | 21.74% | SMA20 | -5.80% | Beta | 0.55 | Target Price | 107.33 |
| Payout | 0.00% | Debt/Eq | 0.46 | Sales Q/Q | 8.33% | SMA50 | -4.70% | Rel Volume | 1.63 | Prev Close | 86.24 |
| Employees | 7,500 | LT Debt/Eq | 0.46 | Earnings | Feb 23 | SMA200 | 9.55% | Avg Volume | 738.25K | Price | 84.31 |
| IPO Date | May 14, 1990 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 7.77% 1.38% | Net Debt/EBITDA | 0.81 | Volume | 1,202,811 | Change | -2.24% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-30-26 | Reiterated | Needham | Buy | $101 → $106 |
| Oct-30-26 | Reiterated | Canaccord Genuity | Buy | $94 → $121 |
| Jul-31-26 | Reiterated | Barrington | Outperform | $107 → $114 |
| Jul-31-26 | Reiterated | Raymond James | Outperform | $83 → $100 |
| Jul-31-26 | Reiterated | Robert W. Baird | $89 → $98 | |
| Jul-31-26 | Reiterated | Needham | Buy | $105 → $101 |
| Jul-31-26 | Reiterated | BTIG | Buy | $107 → $105 |
| May-01-26 | Reiterated | Robert W. Baird | $92 → $83 | |
| Apr-20-26 | Reiterated | Compass Point | $109 → $107 | |
| Apr-17-26 | Reiterated | Piper Sandler | Overweight | $106 → $96 |
Merit Medical Systems, Inc. (MMSI) is engaged in the design, development, manufacturing, and worldwide commercialization of disposable medical products. These devices are crucial for a broad spectrum of diagnostic, therapeutic, and interventional procedures, primarily within the fields of cardiology, radiology, oncology, critical care, and endoscopy. The company operates through two main divisions: Cardiovascular and Endoscopy. Its extensive product portfolio includes advanced solutions for diagnosing and treating conditions in peripheral vessels and organs, as well as a comprehensive suite of cardiac intervention products. The latter encompasses tools for vascular access, angiography, electrophysiology, cardiac rhythm management, fluid and hemodynamic monitoring, hemostasis, and various interventional therapies for heart-related ailments. Additionally, MMSI provides customized procedural solutions, offering critical care items, disinfection protection systems, specialized syringes, manifold kits, and tailored trays and packs. Their offerings further extend to coated tubes and wires, alongside sophisticated sensor components for microelectromechanical systems (MEMS). The company also features pulmonary products, such as laser-cut tracheobronchial stents with their accompanying over-the-wire and direct visualization delivery systems, and dilation balloons used for endoscopic stricture dilation. Gastroenterology products, as well as essential kits and accessories for endoscopy and bronchoscopy procedures, complete their diverse catalog. Merit Medical Systems sells its products to a wide client base, including hospitals and healthcare professionals (physicians, technicians, and nurses) working in alternative care settings. Distribution channels include a direct sales force, authorized distributors, original equipment manufacturer (OEM) partnerships, and custom procedure tray manufacturers, reaching customers throughout the United States and internationally. Founded in 1987, Merit Medical Systems, Inc. has its corporate headquarters situated in South Jordan, Utah.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,611 | 1,515 | 1,357 | 1,257 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 816 | 778 | 713 | 673 | — | — | — | — | — | |
| Gross Profit | 796 | 737 | 643 | 584 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 482 | 455 | 377 | 374 | — | — | — | — | — | |
| Research and Development | 97 | 97 | 84 | 83 | — | — | — | — | — | |
| Other Operating Expense | 0 | 1 | 27 | 2 | — | — | — | — | — | |
| Operating Income | 218 | 184 | 156 | 124 | — | — | — | — | — | |
| Interest Expense | 32 | 26 | 31 | 16 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 26 | 13 | 26 | 4 | — | — | — | — | — | |
| Net Income Before Taxes | 212 | 171 | 150 | 112 | — | — | — | — | — | |
| Income Taxes | 52 | 42 | 30 | 18 | — | — | — | — | — | |
| Consolidated Net Income | 160 | 128 | 120 | 94 | — | — | — | — | — | |
| Net Income From Continuing Operations | 160 | 128 | 120 | 94 | — | — | — | — | — | |
| Net Income | 160 | 128 | 120 | 94 | — | — | — | — | — | |
| EPS (Recurring) | 2.69 | 2.17 | 2.07 | 1.64 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.69 | 2.17 | 2.07 | 1.64 | — | — | — | — | — | |
| EPS (Diluted) | 2.66 | 2.13 | 2.03 | 1.62 | — | — | — | — | — | |
| EBITDA | 377 | 332 | 274 | 229 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 31.70 | 41.38 | 47.65 | 46.89 | — | — | — | — | — | |
| Price To Sales Ratio | 3.14 | 3.43 | 4.13 | 3.50 | — | — | — | — | — | |
| Gross Margin | 49.41 | 48.65 | 47.38 | 46.46 | — | — | — | — | — | |
| Operating Margin | 13.53 | 12.15 | 11.50 | 9.86 | — | — | — | — | — | |
| Net Margin | 9.93 | 8.45 | 8.84 | 7.48 | — | — | — | — | — | |
| Shares Outstanding | 60 | 59 | 58 | 58 | — | — | — | — | — | |
| Market Capitalization | 5,059 | 5,200 | 5,610 | 4,406 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Peterson Neil W. | CHIEF OPERATING OFFICER | Aug 24 '26 | Sale | 90.45 | 7,500 | 678,360 | 18,051 | Aug 25 |
| Peterson Neil W. | CHIEF OPERATING OFFICER | Aug 04 '26 | Sale | 85.00 | 21,449 | 1,823,165 | 25,551 | Aug 05 |
| Gunderson Thomas J. | Director | May 20 '26 | Option Exercise | 52.17 | 21,250 | 1,108,613 | 60,741 | May 21 |
| Smith Christian Adam | Chief Commercial Officer | May 11 '26 | Buy | 61.00 | 1,626 | 99,186 | 2,220 | May 13 |
| Ward Lynne N. | Director | May 07 '26 | Sale | 62.61 | 5,000 | 313,035 | 7,809 | May 11 |
| Lloyd Brian G. | CHIEF LEGAL OFFICER, SECRETARY | May 07 '26 | Buy | 62.63 | 2,000 | 125,250 | 2,000 | May 11 |
| Aronson Martha Goldberg | President and CEO | May 06 '26 | Buy | 60.44 | 2,000 | 120,880 | 49,792 | May 07 |
| Parra Raul Jr. | CFO AND TREASURER | May 06 '26 | Buy | 61.01 | 1,500 | 91,515 | 58,843 | May 07 |
| Voigt Michel J. | CHIEF HUMAN RESOURCES OFFICER | May 05 '26 | Buy | 60.65 | 2,250 | 136,463 | 2,265 | May 07 |
| Peterson Neil W. | CHIEF OPERATING OFFICER | Jan 06 '26 | Option Exercise | 54.40 | 5,000 | 272,000 | 33,369 | Jan 08 |
| Peterson Neil W. | CHIEF OPERATING OFFICER | Jan 06 '26 | Sale | 90.00 | 5,000 | 450,000 | 28,369 | Jan 08 |
| Lampropoulos Fred P. | Executive Chairman | Nov 25 '25 | Sale | 88.04 | 10,000 | 880,377 | 1,019,955 | Nov 26 |
| Lampropoulos Fred P. | Executive Chairman | Nov 21 '25 | Sale | 87.31 | 25,000 | 2,182,750 | 1,029,955 | Nov 24 |
| Lampropoulos Fred P. | Executive Chairman | Nov 20 '25 | Sale | 85.13 | 20,000 | 1,702,650 | 1,054,955 | Nov 21 |
| Lampropoulos Fred P. | Executive Chairman | Nov 18 '25 | Sale | 84.83 | 5,000 | 424,130 | 1,074,955 | Nov 20 |